Nefiracetam is a lab-made cognition compound developed in the 1980s to treat memory loss. Animal studies consistently show it can restore memory and protect brain tissue after injury, but human trials in dementia, depression, and apathy were largely negative. It was never approved, its long-term safety is unknown, and today's unregulated supply is unverified. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT (alanine aminotransferase) | ~10–26 U/L (women), ~10–33 U/L (men) | Detects liver stress from hepatic metabolism |
| AST (aspartate aminotransferase) | ~10–26 U/L | Complements ALT for liver-cell injury |
| eGFR (estimated glomerular filtration rate) | >90 mL/min/1.73m² | Screens for kidney effects flagged in animal studies |
| Creatinine | ~0.6–1.1 mg/dL (women), ~0.7–1.2 mg/dL (men) | Direct kidney-function marker underlying eGFR |
| Urine specific gravity / concentration | 1.010–1.025 | Early animal kidney injury reduced urine concentrating ability |
Cadence: Baseline before first dose, recheck at 4–8 weeks after starting, then every 3–6 months with continued use and any time new symptoms appear